Understanding the mechanisms of ONOO− reduction by the E2 domain of APP is crucial not only for expanding the scope and significance of copper proteins in ONOO− reduction but also for elucidating their physiological and pathological roles, particularly in the context of Alzheimer's disease. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.